Protagonist Therapeutics, Inc Earnings Per Share, Basic and Diluted
Protagonist Therapeutics, Inc (PTGX) reported Earnings Per Share, Basic and Diluted of -$0.84 per share for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-08-04
- Protagonist Therapeutics, Inc earnings per share, basic and diluted for the quarter ending 2022-06-30 was -$0.84.
- Protagonist Therapeutics, Inc earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.43.
- Protagonist Therapeutics, Inc earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.70.
- Protagonist Therapeutics, Inc earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.69.
- Protagonist Therapeutics, Inc earnings per share, basic and diluted for fiscal 2021 was -$2.71.
- Protagonist Therapeutics, Inc earnings per share, basic and diluted for fiscal 2020 was -$1.92.
- Protagonist Therapeutics, Inc earnings per share, basic and diluted for fiscal 2019 was -$2.98.
- Protagonist Therapeutics, Inc earnings per share, basic and diluted for fiscal 2018 was -$1.74.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$0.84 10-Q · filed 2022-08-04 | -$1.27 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | -$0.43 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | -$2.71 10-K · filed 2022-02-28 | |||
| 2021-09-30 | -$0.70 10-Q · filed 2021-11-03 | -$1.94 10-Q · filed 2021-11-03 | ||
| 2021-06-30 | -$0.69 10-Q · filed 2022-08-04 | -$1.23 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$0.54 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$1.92 10-K · filed 2022-02-28 | |||
| 2020-09-30 | -$0.21 10-Q · filed 2021-11-03 | -$1.45 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | -$0.59 10-Q · filed 2021-08-04 | -$1.31 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | -$0.72 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | -$0.63 10-K · filed 2020-03-10 | -$2.98 10-K · filed 2022-02-28 | ||
| 2019-09-30 | -$0.61 10-Q · filed 2020-11-04 | -$2.36 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | -$1.18 10-Q · filed 2020-08-06 | -$1.77 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | -$0.58 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | -$0.57 10-K · filed 2020-03-10 | -$1.74 10-K · filed 2021-03-10 | ||
| 2018-09-30 | -$0.38 10-K · filed 2020-03-10 | -$1.15 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | -$0.41 10-K · filed 2020-03-10 | -$0.77 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | -$0.36 10-K · filed 2020-03-10 | |||
| 2017-12-31 | -$0.15 10-K · filed 2019-03-12 | -$0.42 derived: net income ÷ weighted average shares · filed 2020-03-10 | -$1.27 derived: net income ÷ weighted average shares · filed 2020-03-10 | -$2.09 10-K · filed 2020-03-10 |
| 2017-09-30 | -$0.29 10-K · filed 2019-03-12 | -$1.17 derived: net income ÷ weighted average shares · filed 2018-11-06 | -$2.01 10-Q · filed 2018-11-06 | -$2.68 derived: net income ÷ weighted average shares · filed 2019-03-12 |
| 2017-06-30 | -$0.89 10-K · filed 2019-03-12 | -$1.73 10-Q · filed 2018-08-07 | -$2.40 derived: net income ÷ weighted average shares · filed 2019-03-12 | -$3.24 derived: net income ÷ weighted average shares · filed 2019-03-12 |
| 2017-03-31 | -$0.84 10-K · filed 2019-03-12 | -$1.51 derived: net income ÷ weighted average shares · filed 2019-03-12 | -$2.34 derived: net income ÷ weighted average shares · filed 2019-03-12 | -$3.78 derived: net income ÷ weighted average shares · filed 2019-03-12 |
| 2016-12-31 | -$0.67 10-K · filed 2018-03-07 | -$1.47 derived: net income ÷ weighted average shares · filed 2019-03-12 | -$3.03 derived: net income ÷ weighted average shares · filed 2019-03-12 | -$5.80 10-K · filed 2019-03-12 |
| 2016-09-30 | -$0.87 10-K · filed 2018-03-07 | -$3.32 derived: net income ÷ weighted average shares · filed 2017-11-07 | -$8.62 10-Q · filed 2017-11-07 | -$13.59 derived: net income ÷ weighted average shares · filed 2018-03-07 |
| 2016-06-30 | -$19.07 10-K · filed 2018-03-07 | -$56.90 10-Q · filed 2017-08-08 | -$78.42 derived: net income ÷ weighted average shares · filed 2018-03-07 | -$92.59 derived: net income ÷ weighted average shares · filed 2018-03-07 |
| 2016-03-31 | -$40.96 10-K · filed 2018-03-07 | -$61.99 derived: net income ÷ weighted average shares · filed 2018-03-07 | -$75.09 derived: net income ÷ weighted average shares · filed 2018-03-07 | -$90.25 derived: net income ÷ weighted average shares · filed 2018-03-07 |
| 2015-12-31 | -$20.31 10-K · filed 2017-03-07 | -$33.19 derived: net income ÷ weighted average shares · filed 2018-03-07 | -$47.25 derived: net income ÷ weighted average shares · filed 2018-03-07 | -$59.32 10-K · filed 2018-03-07 |
| 2015-09-30 | -$12.79 10-K · filed 2017-03-07 | -$26.50 derived: net income ÷ weighted average shares · filed 2016-11-14 | -$38.32 10-Q · filed 2016-11-14 | |
| 2015-06-30 | -$13.78 10-K · filed 2017-03-07 | -$25.55 10-Q · filed 2016-09-15 | ||
| 2015-03-31 | -$11.75 10-K · filed 2017-03-07 | |||
| 2014-12-31 | -$49.38 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |